Boron Drug Development | Heron Neutron Medical Corp.

Innovative Treatment Options by AB-BNCT Patients Cured and Maintain Quality of Life

Home Product & Service Boron Drug Development

產品與服務

Product & Service

硼中子捕獲治療

Boron Neutron
Capture Therapy

The effectiveness of Boron Neutron Capture Therapy (BNCT) relies heavily on the selection of boron-containing drugs and their biodistribution characteristics. Since the development of BNCT, one of the primary research objectives has been the development of boron compounds capable of achieving differential accumulation between tumor tissues and normal tissues.

01

One of the most widely studied boron agents in clinical BNCT research is Borofalan (10B) (L-4-Boronophenylalanine, BPA). Structurally similar to a naturally occurring amino acid, BPA has been utilized in multiple clinical studies and BNCT treatment programs. With advances in drug design and manufacturing technologies, ongoing research continues to focus on improving its biodistribution properties and administration strategies to further support the clinical development of BNCT.
02

L-4-Boronophenylalanine (BPA) is a boron-containing amino acid analog that enters cells through the L-type Amino Acid Transporter 1 (LAT1) expressed on the cell membrane. Because LAT1 is typically overexpressed in many tumor cells, BPA preferentially accumulates within tumors, resulting in a higher local boron concentration compared to surrounding normal tissues.
03

When boron-containing cells are exposed to a neutron beam, boron atoms undergo a nuclear capture reaction that releases high-energy alpha particles (α particles) and lithium nuclei (⁷Li). The path length of these particles is limited to the cellular scale, enabling highly localized energy deposition within tumor cells while minimizing damage to adjacent healthy tissues.

¹⁰B + n → ⁷Li + α + Energy

This unique mechanism allows BNCT to selectively target boron-loaded tumor cells while preserving surrounding normal tissues.

Disease Overview

Head and neck cancer refers to a group of malignant tumors arising in the oral cavity, pharynx, larynx, nasal cavity, and other related regions of the head and neck. It has a relatively high incidence in Asia. Common types include oral cavity cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, and nasopharyngeal cancer：

Oral Cancer

Buccal Mucosa Cancer

Oropharyngeal Cancer

Laryngeal Cancer
Tongue Cancer

Gingival Cancer

Hypopharyngeal Cancer

Nasal Cavity and Paranasal Sinus Cancer
Floor of Mouth Cancer

Hard Palate Cancer

Nasopharyngeal Cancer

Salivary Gland Cancer

Current standard treatment options for head and neck cancer include surgery, radiation therapy, and systemic drug therapy. Through a multidisciplinary treatment approach, many patients can achieve effective disease control. However, some patients may still experience tumor recurrence or local disease progression after completing treatment, leading to recurrent head and neck cancer.

Patients with recurrent head and neck cancer have often previously undergone high-dose radiotherapy, surgery, and/or systemic therapies, which can significantly limit subsequent treatment options. As a result, clinical management and treatment planning for these patients become considerably more challenging and complex.

Unmet Medical Need

For patients with recurrent head and neck cancer, currently available clinical management options may include repeat surgery, re-irradiation, and systemic drug therapy. However, several challenges remain in clinical practice:

Previous treatments may have already reached tissue tolerance limits, restricting subsequent treatment options.
The risk to surrounding normal tissues must be carefully evaluated before any additional intervention.
Each treatment modality has inherent limitations regarding patient eligibility and implementation requirements.

As a result, there is an ongoing effort to explore treatment approaches based on different mechanisms of action for this patient population, with the aim of evaluating their potential role in terms of safety and clinical feasibility.

Clinical Significance

This clinical trial aims to evaluate the safety and feasibility of Boron Neutron Capture Therapy (BNCT) in patients with recurrent head and neck cancer.

Treatment Mechanism -

BNCT is a treatment modality that combines a boron-containing drug with neutron irradiation. The basic concept is as follows:

Boron-containing drug is administered to the patient, allowing it to distribute within the body.
The patient is then exposed to neutron irradiation to induce a nuclear reaction.
The resulting reaction produces effects at the cellular level.

This treatment mechanism differs from that of conventional radiotherapy and remains a medical technology under ongoing research and development.

Clinical Significance -

The primary objectives of this study include:

Evaluating the safety of this treatment approach in patients with recurrent head and neck cancer
Assessing its feasibility in clinical application
Providing a reference for future research and the development of related treatment approaches

Important Information About the Clinical Trial

This study is a clinical trial designed to collect relevant clinical data to evaluate the safety and feasibility of the treatment approach.

BNCT has not yet been approved as a standard treatment modality for routine clinical use. Its clinical efficacy and potential risks require further evaluation and confirmation through clinical research.

Compassionate Use

Compassionate Use refers to a regulatory pathway that allows patients with serious or life-threatening diseases to access investigational medical technologies or products under specific circumstances. When approved treatment options are unavailable, ineffective, unsuitable, or when no other feasible therapeutic alternatives exist, physicians may evaluate the patient's condition and, in accordance with applicable regulatory requirements and ethical standards, consider the use of medical technologies or products that have not yet received full regulatory approval or remain under clinical development. The implementation of compassionate use must comply with the requirements of local regulatory authorities and healthcare institutions. Prior approval through appropriate ethical review processes, such as an Institutional Review Board (IRB) or ethics committee, is required before treatment can be provided. Compassionate use represents an exceptional access pathway and is not considered a standard or routine treatment approach. Its application requires comprehensive risk assessment, informed patient consent, and close medical supervision to ensure patient safety and ethical clinical practice.

BNCT is a highly specialized treatment modality that must be evaluated by a physician based on the tumor type, disease stage, and the patient's overall condition. We recommend consulting a medical institution with experience in BNCT, where a specialist can assess whether this treatment or any relevant clinical trial opportunities may be appropriate for the patient.

Contact

If you have any questions, please feel free to contact us.

AB-BNCT 醫療設備